In a major win for healthcare innovation, Catalio Capital Management has closed its fourth venture fund with over $400 million in commitments.
The New York-based investment firm—known for backing science-driven startups—has once again caught the attention of big-name institutional players from around the world.
A Mix of Loyal and New Investors
The latest round, dubbed Catalio Nexus Fund IV, brought in strong support not just from long-time backers, but also from a wave of new investors, including foundations, endowments, RIAs, and global institutions.
That broad investor mix is a sign of confidence in Catalio’s unique strategy and growing influence in the healthcare investment space.
Staying True to Their Scientific Roots
Catalio has always taken a distinct approach: investing in biotech and healthcare startups spun out of top-tier academic labs.
They zero in on companies led by experienced founders with deep scientific credentials—often repeat entrepreneurs—who are pushing the boundaries of life sciences and medical technology.
Since the firm launched in 2020, the Nexus fund family has backed more than 80 private companies and has already seen several exits via acquisitions and IPOs.
Fund IV Already Making Bold Bets
Even though it’s relatively new, Fund IV has already invested in 16 companies, and the roster reflects Catalio’s appetite for bold, category-defining ventures.
Some of the standouts include:
-
Co-leading PinkDx’s $40 million Series A, which focuses on cancer diagnostics
-
Backing Superluminal Medicines in their Series A round
-
Launching Rhapsogen and TBD Pharma, both co-founded by renowned Catalio Venture Partners with ties to Rockefeller University and Johns Hopkins
-
Joining Imperative Care’s massive $150M Series E, a major medical device deal
-
Investing in Protara Therapeutics via PIPE (NASDAQ: TARA)
-
Participating in the $180M Series D for Alentis Therapeutics
Rapid Growth Since 2020
Catalio was co-founded just five years ago by George Petrocheilos and Dr. Jacob Vogelstein, and in that short time, they’ve grown the firm into a serious force.
Today, they manage $2 billion in assets across private equity, credit, and public equity platforms. That’s a huge leap in just half a decade.
Offices on Both Sides of the Atlantic
With teams based in New York, London, and Washington, D.C., Catalio has a strong presence in two of the world’s most influential financial and scientific hubs.
That international reach has only strengthened their access to top-tier academic breakthroughs—and the people behind them.
